{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T04:27:26Z","timestamp":1729225646555,"version":"3.27.0"},"reference-count":24,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2021,7,9]]},"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1183\/20734735.0056-2021","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T08:14:36Z","timestamp":1633421676000},"page":"210056","update-policy":"http:\/\/dx.doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim?"],"prefix":"10.1183","volume":"17","author":[{"given":"Adilia","family":"Warris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2021,10,4]]},"reference":[{"key":"2024101703580850000_17.3.210056.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405870"},{"key":"2024101703580850000_17.3.210056.2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv418"},{"key":"2024101703580850000_17.3.210056.3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/apa.14891","article-title":"Mycoplasma pneumoniae detection in children with respiratory tract infections and influence on management \u2013 a retrospective cohort study in Switzerland","volume":"109","author":"Deirig","year":"2020","journal-title":"Acta Paediatr"},{"key":"2024101703580850000_17.3.210056.4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy419"},{"key":"2024101703580850000_17.3.210056.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00199112"},{"key":"2024101703580850000_17.3.210056.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1176-3"},{"key":"2024101703580850000_17.3.210056.7","unstructured":"European Centre for Disease Prevention and Control . Antimicrobial resistance in the EU\/EEA (EARS-Net) \u2013 Annual Epidemiological Report 2019. Stockholm, ECDC , 2020. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/surveillance-antimicrobial-resistance-Europe-2019.pdf"},{"key":"2024101703580850000_17.3.210056.8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/INF.0000000000001477","article-title":"Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014","volume":"36","author":"Pfaller","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2024101703580850000_17.3.210056.9","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2016.00329"},{"key":"2024101703580850000_17.3.210056.10","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1080\/20469047.2017.1409455","article-title":"Antibiotic use for community-acquired pneumonia in neonates and children: WHO evidence review","volume":"38","author":"Mathur","year":"2018","journal-title":"Paediatr Int Child Health"},{"key":"2024101703580850000_17.3.210056.11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jpids\/pix083","article-title":"Macrolides in children with community-acquired pneumonia: panacea or placebo?","volume":"7","author":"Blyth","year":"2018","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2024101703580850000_17.3.210056.12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004875.pub5"},{"key":"2024101703580850000_17.3.210056.13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jpeds.2020.10.005","article-title":"Antibiotic choice and clinical outcomes in ambulatory children with community-acquired pneumonia","volume":"229","author":"Lipsett","year":"2021","journal-title":"J Pediatr"},{"key":"2024101703580850000_17.3.210056.14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/INF.0000000000002934","article-title":"Antibiotic prescriptions for children with community-acquired pneumonia: findings from Italy","volume":"40","author":"Costenaro","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2024101703580850000_17.3.210056.15","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-019-00276-3","article-title":"Ambulatory antibiotic prescribing for children with pneumonia after publication of national guidelines: a cross-sectional retrospective study","volume":"9","author":"Poole","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2024101703580850000_17.3.210056.16","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jpids\/piz026","article-title":"Diagnostic testing and antibiotic use in young children with community-acquired pneumonia in the United States, 2008\u20132015","volume":"9","author":"Florin","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"2024101703580850000_17.3.210056.17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2331"},{"key":"2024101703580850000_17.3.210056.18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3047"},{"key":"2024101703580850000_17.3.210056.19","doi-asserted-by":"crossref","first-page":"e0193581","DOI":"10.1371\/journal.pone.0193581","article-title":"Effects of clinical pathway implementation on antibiotic prescriptions for pediatric community-acquired pneumonia","volume":"13","author":"Dona","year":"2018","journal-title":"PLoS One"},{"key":"2024101703580850000_17.3.210056.20","unstructured":"Paediatric Formulary Committee . BNF for Children 2016\u20132017. Vol. 12. London, BMJ Group, Pharmaceutical Press and RCPCH Publications , 2016."},{"key":"2024101703580850000_17.3.210056.21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/pch\/20.8.441","article-title":"Uncomplicated pneumonia in healthy Canadian children and youth: practice points for management","volume":"20","author":"Le Saux","year":"2015","journal-title":"Pediatr Child Health"},{"key":"2024101703580850000_17.3.210056.22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10096-019-03473-7","article-title":"Macrolide prescription in Dutch children: compliance with guidelines","volume":"38","author":"Bandell","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024101703580850000_17.3.210056.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.6287"},{"key":"2024101703580850000_17.3.210056.24","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pis054"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0056-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:41:22Z","timestamp":1729165282000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0056-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,10,4]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1183\/20734735.0056-2021"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0056-2021","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"type":"print","value":"1810-6838"},{"type":"electronic","value":"2073-4735"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}